Buprenorphine for Mucositis in Head and Neck Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a single-arm prospective clinical trial to determine the safety and feasibility of using transdermal buprenorphine in alleviation of radiation induced mucositis pain in head and neck cancer patients.
Who Is on the Research Team?
Stuart J. Wong, MD
Principal Investigator
Medical College of Wisconsin
Are You a Good Fit for This Trial?
Adults aged 18-80 with head and neck cancer undergoing radiation, possibly with chemotherapy. They must have good organ function, no history of substance abuse or certain heart conditions, not be on antidepressants or antipsychotics, and can't be pregnant. Participants need to understand consent forms and use a smartphone app for pain assessment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive radiation therapy for head and neck cancer
Treatment
Participants receive transdermal buprenorphine and oral tramadol for pain management
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Buprenorphine
Buprenorphine is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical College of Wisconsin
Lead Sponsor